NDRA · ENDRA Life Sciences Inc. · Executive Compensation
$6.06
+0.18 (+3.06%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, management believes that without the closing of the Merger, given our current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about our ability to continue as a going concern after the date that is one year from the date that these financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$9.06M
Shares
1.50M
Volume · Oct 2
39.79K
Avg daily vol (3M)
36.4K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Francois Michelon | Former Chief Executive Officer (until August 12, 2024) | $314,650 |
| Michael Thornton | Chief Technology Officer | $222,082 |
| Alexander Tokman | Chief Executive Officer (since August 13, 2024) | $215,185 |
| Irina Pestrikova | Former Senior Director, Finance (until August 8, 2024) | $126,298 |
| Richard Jacroux | Chief Financial Officer (since August 8, 2024) | $95,900 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Francois Michelon | Former Chief Executive Officer (until August 12, 2024) | $646,787 |
| Michael Thornton | Chief Technology Officer | $531,977 |
| Irina Pestrikova | Former Senior Director, Finance (until August 8, 2024) | $214,724 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Alexander Tokman | director | Appointed | 2025-12-15 |
| Michael Harsh | director | Appointed | 2025-12-15 |
| Anthony DiGiandomenico | director | Appointed | 2025-12-15 |
| Louis J. Basenese | director | Appointed | 2025-12-15 |
| Michael Thornton | Chief Technology Officer | Resigned | 2025-11-28 |
| Alexander Tokman | Chairman | Appointed | 2024-08-13 |
| Ziad Rouag | Head of Regulatory and Clinical Affairs | Appointed | 2024-08-13 |
| Richard Jacroux | Chief Financial Officer | Appointed | 2024-08-13 |
| Alexander Tokman | acting Chief Executive Officer | Appointed | 2024-08-13 |
| Francois Michelon | member of the Company’s Board of Directors | Resigned | 2024-08-13 |
| Francois Michelon | Chief Executive Officer | Resigned | 2024-08-13 |
| Irina Pestrikova | Senior Director, Finance | Resigned | 2024-08-09 |
| Renaud Maloberti | Chief Commercial Officer | Resigned | 2022-12-23 |